Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Mar 29, 2021 (6 years ago)

Lidocaine Ointment USP

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Failed Stability Specifications: product did not meet viscosity results.

Cause type: Stability / shelf life

The product degraded or failed stability testing before its labeled expiry. Heat, moisture or time can break the drug down into degradants or reduce potency. All stability / shelf life recalls.

What was recalled

Lidocaine Ointment USP, 5%, NET WT 35.44 g (1 1/4 Oz) tube, Rx Only, Teligent Pharma Inc., Buena, New Jersey, 08310, NDC 52565-008-14.

Affected NDC 52565-0008-14

Compare with the code on your package — it is the most precise check available.

Drug: Lidocaine

Recalling firm
Teligent Pharma, Inc.
NDC code
52565-008-14
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0331-2021 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Lidocaine recalls

See all
Class II · Moderate risk

Lidocaine Ointment USP

Failed Content Uniformity Specifications. Out of Specification for Assay during analysis at the 24- month long term stability station, at (25¿C,60%RH).

Ongoing Wrong potency / content Sun Pharma /Taro D-0848-2026
Class III · Low risk

Lidolog Kit

Labeling: Not Elsewhere Classified: The label wrap covers the barcode, making it hard to scan

Ongoing Labeling / mix-up Asclemed USA Inc. D-0713-2026

Other recalls by Teligent Pharma, Inc.

All 2021 recalls
Class II · Moderate risk

Lidocaine Ointment USP

cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program.

Terminated Stability / shelf life Teligent Pharma, Inc. NDC 50383-341-35 D-0705-2022
Class II · Moderate risk

Lidocaine Cream 4%

cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program.

Terminated Stability / shelf life Teligent Pharma, Inc. NDC 0536-1281-28 D-0704-2022
Class II · Moderate risk

Hydrocortisone Butyrate Lotion

cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program.

Terminated Stability / shelf life Teligent Pharma, Inc. NDC 70512-032-04 D-0703-2022
Class II · Moderate risk

Gentamicin Sulfate Cream USP

cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program.

Terminated Stability / shelf life Teligent Pharma, Inc. NDC 70512-036-30 D-0702-2022